The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Ven, Peter M. van de; Robinson, Hannah; Houten, Marlies A. van; Wildenbeest, Joanne G; Billard, Marie-Noëlle; Zuurbier, Roy P; Korsten, Koos; Houten, Marlies van; Langedijk, Annefleur C; Ven, Peter van de; Bont, Louis; Drysdale, Simon B.; McGinley, Joseph; Lin, Gu-Lung; Snape, Matthew D; Pollard, Andrew J.; Ives, Andrew; Wolfenden, Helen; Salgia, Sanjay; Shetty, Rohoth; Dacosta-Urbieta, Ana; Rivero‐Calle, Irene; Gómez-Carballa, Alberto; Pischedda, Sara; Rodrı́guez-Tenreiro, Carmen; Martinón-Torres, Federico; Heikkinen, Terho; Cunningham, Steve; Nair, Harish; Campbell, Harry; O'Neill, Thomas; Miller, Margaret A.; Baggott, Julie; Beveridge, Catherine; McKernan, Rachael; Rizkalla, Bishoy; Beutels, Philippe; Openshaw, Peter; Meijer, Adam; Fischer, Thea Kølsen; Berge, Maarten van den; Giaquinto, Carlo; Abram, Michael E.; Swanson, Kena A.; Aerssens, Jeroen; Vernhes, Charlotte; Gallichan, Scott; Kumar, Veena R.; Molero, Eva

doi:10.1016/s2213-2600(22)00414-3

Cited by 99 publications

(69 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our estimated number of average admissions per year for Spain in this age group was 14,446 (95%CI 12,662) and this reflects our hospitalisation estimate not being restricted to bronchiolitis, but all respiratory hospitalisations. Moreover, as reported for England by Green et al [29], there is an observed general increase in RSV-associated admissions over the years that may be due to changes in healthcare policies (an increase in hospital bed availability or a change in the admission threshold) and this may explain the higher number of hospitalisations estimated by our study for Spain. Our study also shows how hospitalisations due to RSV in children under 5 years represent one of the leading causes of EU infant hospitalisations (Table 5): based on our estimates, up to 1 in 10 hospitalized children under 5 years of age may be associated to RSV, and this number is larger (around 4 out of 10 children in Italy, Portugal, Denmark and Finland, 1 out of 2 in Sweden) if we only consider respiratory hospitalisations (Table 5).…”

Section: Whilst It Is Important To Properly Understand the Real Burde...supporting

confidence: 71%

Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Riccio

Spreeuwenberg

Osei‐Yeboah

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Respiratory syncytial virus (RSV) infections cause an estimated 22-50 million episodes of acute lower respiratory infections (ALRI) every year in children younger than 5 years. To date, no overall estimate of RSV-associated hospitalisations in children under 5 years has been published for the European Union (EU). Through statistical modelling, we estimated the RSV hospitalisation burden in children under 5 years of age in EU countries and Norway, by age group and country. Methods: We collated national RSV-associated hospitalisation estimates calculated using linear regression models in children under 5 years via the RESCEU project for Denmark, England, Finland, Norway, the Netherlands and Scotland during 2006-2018. A systematic literature review was conducted to collect additional estimates. Using the multiple imputation and nearest neighbor matching extrapolation methods, we estimated RSV-associated hospitalisation rates in all EU countries. Results: Additional estimates for Spain and France were found in the literature and added to the analysis. We estimated that an average of 245,244 (95%CI 224,688-265,799) hospital admissions with a respiratory infection per year were associated with RSV in children under the age of 5, with most cases occurring among children aged less than 1 year (75%). Infants aged less than 2 months represented the most affected group (71.6 per 1,000 children; 95%CI: 66.6-76.6). The hospitalisation rates varied widely across countries: for example, estimated rates in the 0-2 months age group ranged from 47.4 (37.5-57.3) per 1,000 in the Netherlands to 98.3 (88.5-108.1) per 1,000 in France. Conclusion: To our knowledge, this is the first attempt to estimate the overall RSV hospitalisation burden in children under the age of 5 years in the EU. Our findings will help support decisions regarding prevention efforts, and they will also represent an important benchmark to understand changes in the RSV burden following the introduction of RSV immunisation programs in Europe.

show abstract

Section: Whilst It Is Important To Properly Understand the Real Burde...supporting

confidence: 71%

Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Riccio

Spreeuwenberg

Osei‐Yeboah

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although most RSV-associated deaths occur in resource-limited countries, RSV is associated with substantial morbidity and healthcare resource utilisation worldwide, including in high-income European countries [ 3 , 4 , 13 , 14 , 33 , 34 ]. A retrospective analysis (funded by Sanofi Pasteur and AstraZeneca) of data on RSV-associated hospitalisations in France covering an 8-year period from 2010 to 2018 found that the number of such hospitalisations in children aged under 5 years ranged from 43,715 to 54,616 per season (Table 1 ) [ 13 ].…”

Section: Epidemiology and The Impact Of Non-pharmaceutical Interventionsmentioning

confidence: 99%

Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities

et al. 2022

View full text Add to dashboard Cite

The highly contagious respiratory syncytial virus (RSV) is responsible for up to approximately 50,000 hospitalisations during each RSV season in children aged under 5 years in France, with the burden greatest in infants younger than 1 year who were born at term. There is a need for a strategy to universally protect young children from RSV infection, and thereby reduce the pressure that RSV places every year on RSV-infected children, their parents, and French healthcare systems. Potential strategies currently undergoing clinical investigation include passive immunisation via maternal vaccination or administration of long-acting monoclonal antibodies at or soon after birth, followed by vaccination later in infancy or childhood. An ongoing partnership and collaboration between parents, public health authorities, and frontline primary healthcare will need to be reinforced once these new RSV prevention strategies are available, to facilitate their use and ensure that all children receive adequate protection from the start of their first RSV season.

show abstract

“…Respiratory syncytial virus (RSV)-associated acute respiratory infection causes substantial morbidity, leading to the hospitalization of 1 in every 56 healthy term–born infants in high-income settings [ 63 ]. An observational study conducted in the Netherlands on 256 neonates reported that those born with 25(OH)D concentrations <20 ng/mL compared with those with >30 ng/mL had an increased risk of developing severe lower respiratory tract infection RSV in the first year of life of 6.0 (95% CI, 1.6–24.9) [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland

et al. 2023

View full text Add to dashboard Cite

Introduction: All epidemiological studies suggest that vitamin D deficiency is prevalent among the Polish general population. Since vitamin D deficiency was shown to be among the risk factors for many diseases and for all-cause mortality, concern about this problem led us to update the previous Polish recommendations. Methods: After reviewing the epidemiological evidence, case-control studies and randomized control trials (RCTs), a Polish multidisciplinary group formulated questions on the recommendations for prophylaxis and treatment of vitamin D deficiency both for the general population and for the risk groups of patients. The scientific evidence of pleiotropic effects of vitamin D as well as the results of panelists’ voting were reviewed and discussed. Thirty-four authors representing different areas of expertise prepared position statements. The consensus group, representing eight Polish/international medical societies and eight national specialist consultants, prepared the final Polish recommendations. Results: Based on networking discussions, the ranges of total serum 25-hydroxyvitamin D concentration indicating vitamin D deficiency [<20 ng/mL (<50 nmol/L)], suboptimal status [20–30 ng/mL (50–75 nmol/L)], and optimal concentration [30–50 ng/mL (75–125 nmol/L)] were confirmed. Practical guidelines for cholecalciferol (vitamin D3) as the first choice for prophylaxis and treatment of vitamin D deficiency were developed. Calcifediol dosing as the second choice for preventing and treating vitamin D deficiency was introduced. Conclusions: Improving the vitamin D status of the general population and treatment of risk groups of patients must be again announced as healthcare policy to reduce a risk of spectrum of diseases. This paper offers consensus statements on prophylaxis and treatment strategies for vitamin D deficiency in Poland.

show abstract

The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study

Cited by 99 publications

References 25 publications

Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Defining the Burden of Disease of RSV in Europe: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study

Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities

Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland

Contact Info

Product

Resources

About